Pilot Study to Evaluate Clinically the Short-Term Efficacy of GlaucoT Glaucoma Treatment Glasses in the Treatment of Primary Open-Angle Glaucoma (GlaucoT)
Glaucot Teknoloji Anonim Sirketi's GlaucoT glasses represent an innovative approach to treating POAG by utilizing flicker light therapy, which has shown promise in neuroprotection. Given the increasing prevalence of glaucoma, projected to affect over 60 million individuals globally, this device could address a significant unmet need in the market. The competitive landscape includes traditional IOP-lowering medications and surgical interventions, but GlaucoT's non-invasive, cost-effective solution may appeal to patients seeking alternatives. Successful outcomes could position Glaucot as a leader in glaucoma management, potentially leading to partnerships or licensing opportunities within the ophthalmic device sector.
Indication: Primary Open-Angle Glaucoma
Modality: medical device
Target: Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).
Sponsor: Glaucot Teknoloji Anonim Sirketi
Source URL: ClinicalTrials.gov
Source updated: Nov 18, 2024
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).
View original source fields
Condition raw: Primary Open-Angle Glaucoma
Condition normalized: Primary Open-Angle Glaucoma
Modality raw: medical device
Modality normalized: medical device
Target raw: Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).
Target normalized: Flicker light therapy targeting neuroprotection and retinal ganglion cell preservation in primary open-angle glaucoma (POAG).